Related Experiment Videos
Neonatal diagnosis of familial type II hyperlipoproteinemia
Insights
Measuring cord serum prebeta-beta-lipoprotein can identify children with familial type II hyperlipoproteinemia. This method is effective when excluding infants with temporary neonatal hypertriglyceridemia and hypercholesterolemia.
Area of Science:
- Cardiovascular Research
- Pediatric Endocrinology
- Clinical Biochemistry
Background:
- Familial hyperlipoproteinemia poses significant cardiovascular risks.
- Early identification of genetic lipid disorders in infants is crucial for timely intervention.
- Cord serum lipid profiles offer a potential window into neonatal metabolic health.
Purpose of the Study:
- To evaluate the utility of cord serum prebeta-beta-lipoprotein levels for detecting familial type II hyperlipoproteinemia in newborns.
- To determine the diagnostic accuracy of this biomarker in a general infant population.
- To differentiate true genetic hyperlipoproteinemia from transient neonatal lipid elevations.
Main Methods:
- Radial immunodiffusion assay used to measure prebeta-beta-lipoprotein in cord serum of 303 infants.
- Established a cut-off limit at the 97.5th percentile (197 mg/100 ml).
- Follow-up studies including family lipid phenotyping to confirm diagnoses.
Main Results:
- Six infants (1.98%) exhibited elevated cord serum prebeta-beta-lipoprotein levels.
- Three of these infants were diagnosed with classic type II hyperlipoproteinemia.
- The remaining three infants with elevated levels had transient neonatal hypertriglyceridemia and/or hypercholesterolemia.
Conclusions:
- Cord serum prebeta-beta-lipoprotein measurement is a viable tool for identifying infants with familial type II hyperlipoproteinemia.
- Exclusion of transient neonatal hypertriglyceridemia and hypercholesterolemia is essential for accurate diagnosis.
- This screening approach aids in early detection of genetic lipid disorders in pediatric populations.
Abstract:
Cord serum prebeta-beta-lipoprotein concentration was measured in a radial immunodiffusion assay in 303 randomly selected, full-term infants whose parental phenotypes were unknown. Six infants had elevated concentrations, that is above a cut-off limit of 197 mg/100 ml (97.5th percentile). Three of these infants suffered from classic type II hyperlipoproteinemia, and this diagnosis was confirmed by family studies at follow-up. The three other infants and their parents were shown to be normolipemic at follow-up. The elevated cord serum prebeta-beta-lipoprotein in these three infants could be explained by highly elevated cord serum triglyceride and/or cholesterol. The 297 infants with normal cord serum prebeta-beta-lipoprotein and their parents were all shown to be normalipemic at follow-up. It is concluded that the measurement of prebeta-beta-lipoportein in cord serum allows the identification of children with familial type II hyperlipoproteinemia, if infants with transient neonatal hypertriglyceridemia and hypercholesterolemia are excluded.